subunitsplit
influenza
vaccin
less
reactogen
compar
whole
viru
vaccin
howev
immunogen
rel
low
thu
requir
proper
adjuv
andor
deliveri
vehicl
immunogen
enhanc
influenza
vaccin
administ
intramuscularli
induc
minimum
mucos
immun
respiratori
mucosa
prime
site
infect
studi
chitosan
cs
nanoparticl
prepar
ionic
crosslink
cs
sodium
tripolyphosph
tpp
cstpp
ratio
use
h
mix
time
cstpp
nanoparticl
use
deliveri
vehicl
intranas
influenza
vaccin
made
hemagglutinin
ha
split
influenza
viru
product
innocu
immunogen
protect
efficaci
cstppha
vaccin
test
influenza
mous
model
comparison
antigen
alon
vaccin
cstppha
nanoparticl
requir
characterist
includ
nanos
posit
charg
high
antigen
encapsul
effici
mice
receiv
two
dose
cstppha
vaccin
intranas
show
advers
symptom
indic
vaccin
innocu
anim
develop
higher
system
mucos
antibodi
respons
vaccin
made
hasplit
influenza
viru
alon
cstppha
vaccin
could
induc
also
cellmedi
immun
respons
shown
high
number
cell
spleen
ha
vaccin
alon
could
besid
cs
nanoparticl
encapsul
hasplit
vaccin
reduc
markedli
influenza
morbid
also
confer
protect
rate
vaccin
mice
lethal
influenza
viru
challeng
overal
result
indic
cs
nanoparticl
invent
studi
effect
safe
deliveri
vehicleadjuv
influenza
vaccin
influenza
highli
contagi
devast
respiratori
diseas
caus
public
health
socioeconom
problem
worldwid
current
avail
influenza
vaccin
made
either
inactiv
whole
virus
viru
subunit
split
product
former
vaccin
highli
immunogen
often
caus
advers
reaction
particularli
infant
children
therefor
mani
countri
prefer
subunit
split
vaccin
peopl
howev
less
reactogen
vaccin
confer
limit
immunogen
requir
either
high
antigen
dose
case
naiv
subject
booster
dose
coadministr
immunolog
adjuv
vaccin
compon
improv
immunogen
lead
antigen
spare
adequ
protect
immun
respons
singl
dose
immunogen
vaccin
enhanc
better
emuls
adjuv
ie
oilinwat
prepar
squalenebas
oilinwat
prepar
alum
due
probabl
recruit
inflammatori
cell
lymphocyt
antigenpres
cell
dendrit
cell
macrophag
nevertheless
emuls
adjuv
also
increas
advers
reaction
local
system
influenza
vaccin
administ
mostli
intramuscular
rout
limit
system
immun
respons
induc
low
would
respiratori
mucos
respons
usual
muscl
littl
antigenpres
cell
includ
dendrit
cell
macrophag
skelet
muscl
express
mhc
molecul
normal
condit
besid
human
muscl
cell
express
homolog
function
coinhibitori
molecul
cell
local
immun
regulatori
process
intranas
rout
influenza
vaccin
administr
contrari
offer
sever
advantag
besid
rout
needleand
painless
evid
indic
also
antigen
activ
immun
cell
nasalassoci
lymphoid
tissu
commonli
home
respiratori
immun
effector
site
includ
larynxand
bronchusassoci
lymphoid
tissu
exert
defens
activ
prime
site
influenza
viru
infect
moreov
vaccin
compon
appli
intranas
may
reach
macrophag
roam
trachea
lung
cell
may
engulf
vaccin
becom
matur
drainag
local
lymph
node
acquir
abil
express
cosign
mhc
molecul
secret
cytokin
present
antigen
cell
induct
local
immun
respons
vaccin
antigen
appli
intranas
may
also
reach
blood
circul
system
immun
respons
stimul
spleen
peripher
lymph
node
thu
mucos
system
immun
respons
expect
intranas
immun
appropri
vaccin
formul
could
overcom
normal
mucos
toler
breach
nasal
epithelium
tight
junction
recent
decad
chitosan
cs
nontox
bioadhes
degrad
compat
materi
use
wide
carrier
peptid
protein
dnabas
vaccin
cs
attract
intranas
vaccin
deliveri
vehicl
mucoadhes
properti
could
overcom
mucociliari
clearanc
thu
increas
resid
time
vaccin
compon
nasal
passag
cs
promot
paracellular
transport
cargo
antigen
nasal
mucosa
serv
immunopotenti
agent
augment
vaccin
immunogen
effect
besid
annot
data
demonstr
cs
nanoparticl
induc
mucos
system
immun
respons
entrap
antigen
intranas
administr
studi
split
influenza
vaccin
contain
hemagglutinin
viru
formul
cs
nanoparticl
administ
intranas
vaccin
innocu
immunogen
protect
efficaci
mous
model
influenza
report
herein
low
viscou
cs
sodium
tripolyphosph
tpp
sigmaaldrich
mo
usa
sodium
acet
trihydr
acet
acid
nacalai
tesqu
kyoto
japan
chemic
reagent
grade
purifi
rat
monoclon
antimous
rat
antimous
conjug
streptavidinhorseradish
peroxidas
hrp
conjug
bd
opteia
tm
assay
diluent
bectondickinson
bd
bioscienc
ca
usa
hrplabel
goat
antimous
igg
iga
southern
biotech
al
usa
tmbe
tmbh
substrat
moss
md
usa
anim
experi
approv
ethic
committe
nation
institut
biomed
innov
nibio
osaka
japan
anim
manipul
perform
accord
nibio
guidelin
care
use
laboratori
anim
femal
balbc
mice
week
old
japan
slc
hamamatsu
japan
maintain
specif
pathogenfre
condit
anim
room
nibio
use
anim
challeng
test
vaccin
protect
efficaci
viru
propag
mardindarbi
canin
kidney
cell
grown
complet
eagl
minimum
essenti
medium
contain
heatinactiv
fetal
bovin
serum
fb
nichirei
bioscienc
tokyo
japan
mm
lglutamin
mgml
sodium
bicarbon
gentamycin
virus
harvest
cultur
supernat
inactiv
ultraviolet
irradi
biosafeti
facil
nibio
cstpp
nanoparticl
prepar
describ
previous
modif
wv
cs
stock
solut
prepar
dissolv
cs
powder
vv
aqueou
acet
acid
magnet
stir
gentl
heat
transpar
solut
obtain
prepar
adjust
ph
filter
membran
work
cs
solut
differ
concentr
ie
prepar
dilut
stock
solut
mm
sodium
acet
buffer
ph
tpp
work
solut
prepar
ultrapur
distil
water
plain
cstpp
nanoparticl
obtain
ionic
crosslink
posit
charg
nitrogen
group
cs
neg
charg
phosphat
group
tpp
preliminari
screen
optim
concentr
cs
tpp
form
colloid
solut
done
mix
variou
work
concentr
cs
ml
solut
tpp
ml
thereaft
select
cs
concentr
mix
vari
amount
tpp
yield
differ
cstpp
mass
ratio
ie
ww
select
cstpp
ratio
form
desir
cstpp
nanoparticl
mix
time
vari
h
investig
effect
nanoparticl
size
encapsul
hasplit
influenza
product
cs
tpp
nanoparticl
perform
mix
ml
contain
hasplit
viru
compon
acet
buffer
ph
ml
wv
cs
solut
ml
tpp
solut
admix
prepar
kept
stir
h
cstppha
nanoparticl
harvest
centrifug
min
pellet
resuspend
ml
steril
pb
morpholog
csencapsul
hasplit
viru
nanoparticl
cstppha
examin
use
transmiss
electron
microscopi
tem
hitachi
tokyo
japan
size
surfac
charg
determin
use
autom
measur
program
zetasizernano
seri
instrument
malvern
worcestershir
uk
order
estim
percent
antigen
encapsul
effici
ee
cstppha
prepar
centrifug
min
ee
calcul
total
amount
hasplit
viru
ad
amount
hasplit
viru
supernat
amount
hasplit
viru
supernat
measur
perform
triplic
cstppha
centrifug
pellet
resuspend
pb
contain
hasplit
viru
product
mice
divid
four
group
five
mice
group
mice
immun
intranas
twice
interv
cstppha
contain
antigen
mice
group
control
receiv
individu
two
dose
interv
hasplit
viru
alon
plain
cstpp
nanoparticl
pb
respect
two
week
booster
mice
bled
antigenspecif
igg
antibodi
sera
determin
indirect
enzymelink
immunosorb
assay
elisa
bleed
bronchoalveolar
lavag
fluid
balf
harvest
mous
flush
ml
pb
contain
gentamycin
via
surflo
teflon
iv
cathet
terumo
tokyo
japan
insert
hole
made
proxim
trachea
lower
respiratori
tract
fluid
drawn
back
cathet
anoth
cathet
use
flush
ml
pb
upward
tracheal
hole
nasal
passag
order
collect
nasal
wash
fluid
nw
balf
nw
centrifug
remov
tissu
cell
debri
supernat
collect
separ
concentr
use
membran
amicon
ultrafiltr
use
antigenspecif
iga
antibodi
determin
indirect
elisa
spleen
asept
excis
mous
singl
cell
prepar
medium
supplement
fb
enumer
antigenspecif
cell
elispot
assay
indirect
elisa
use
determin
antigenspecif
serum
igg
iga
mous
sera
balf
nw
respect
briefli
microtest
tm
elisa
plate
bd
bioscienc
coat
hasplit
vaccin
kept
overnight
wash
pbst
well
block
bd
opteia
tm
assay
diluent
serial
twofold
dilut
sera
start
balf
nw
start
mous
group
ad
appropri
antigenco
well
plate
kept
h
serum
igg
detect
goat
antimous
igghrp
conjug
dilut
ad
well
goat
antimous
igahrp
conjug
dilut
use
specif
iga
detect
balf
nw
plate
incub
h
wash
tmbe
substrat
use
color
develop
enzymat
reaction
stop
ad
n
hcl
od
content
well
determin
blank
well
pb
ad
instead
mous
sampl
specif
antibodi
titer
highest
dilut
sampl
od
number
splenocyt
determin
use
elispot
procedur
briefli
multiscreen
ht
ha
filtrat
plate
millipor
ireland
coat
purifi
rat
monoclon
antimous
antibodi
incub
overnight
plate
wash
well
block
fb
medium
h
singl
spleen
cell
vaccinatedcontrol
mice
ad
appropri
well
cellswel
follow
uvinactiv
pfuwel
optim
amount
titrat
complet
medium
plate
incub
co
incub
h
content
well
discard
well
wash
ad
rat
antimous
conjug
incub
h
streptavidinhrp
conjug
dilut
tmbh
substrat
use
spot
revel
enzymat
reaction
stop
rins
well
distil
water
automat
kselispot
reader
carl
zeiss
oberkochen
germani
use
spot
enumer
data
express
number
spot
per
splenocyt
three
independ
experi
perform
two
set
four
mous
group
five
mice
per
group
prepar
group
set
immun
intranas
cstppha
vaccin
immunogen
studi
group
set
serv
respect
control
two
week
booster
dose
mice
set
challeng
intranas
ld
mouseadapt
set
anim
receiv
individu
ld
viru
intranas
anim
observ
daili
morbid
bodi
weight
loss
mortal
experi
termin
day
postchalleng
data
analyz
use
graphpad
prism
san
diego
ca
usa
differ
among
mous
group
compar
unpair
test
mannwhitney
test
use
normal
obtain
p
valu
statist
differ
optimum
proport
cs
tpp
form
ionic
crosslink
nanoparticl
screen
randomli
total
cstpp
formul
includ
six
cs
work
solut
vol
ml
four
concentr
tpp
work
solut
cstpp
colloid
solut
turbid
obtain
wv
cs
use
final
concentr
mgml
mix
variabl
volum
variou
tpp
solut
data
shown
cs
final
concentr
deviat
mg
ml
either
clear
solut
suspens
precipit
obtain
formul
contain
cs
mgml
yield
colloid
solut
investig
find
optim
tpp
concentr
cstpp
nanoparticl
format
perform
set
cstpp
ratio
ww
experi
ml
wv
cs
final
concentr
mgml
mix
ml
variou
tpp
concentr
wv
equival
final
concentr
mgml
respect
final
volum
prepar
adjust
acet
buffer
ph
ml
found
cstpp
ratio
tabl
tabl
cstpp
ratio
colloid
prepar
vari
cstpp
mix
time
h
result
indic
particl
size
increas
timedepend
manner
ie
longer
mix
period
larger
particl
size
tabl
ii
taken
togeth
optim
condit
produc
cstpp
nanoparticl
mgml
cs
solut
mgml
tpp
solut
cstpp
mass
ratio
h
mix
time
formul
tabl
ii
produc
nanoparticl
nm
use
hasplit
influenza
vaccin
deliveri
vehicl
cstppha
nanoparticl
reveal
spheric
shape
tem
fig
physicochem
characterist
cstppha
vaccin
shown
tabl
iii
zeta
potenti
csformul
hasplit
vaccin
nanoparticl
cathod
rang
mv
size
vaccin
particl
nm
prime
prepar
nm
booster
prepar
larger
respect
plain
cstpp
prepar
nm
respect
p
cstppha
plain
cstpp
reveal
rather
uniform
nanos
cstppha
encapsul
effici
ee
mice
immun
intranas
two
dose
csencapsul
hasplit
viru
vaccin
vaccin
control
show
sign
symptom
advers
effect
csencapsul
hasplit
viru
vaccin
mice
system
mucos
immun
respons
level
haspecif
serum
igg
secretori
iga
balf
nw
mice
vaccin
cstppha
vaccin
ha
alon
plain
cs
tpp
pb
shown
fig
haspecif
igg
antibodi
titer
sera
mice
immun
cstppha
vaccin
significantli
higher
stimul
hasplit
vaccin
alon
plain
cstpp
pb
fig
p
haspecif
iga
level
balf
fig
well
nw
fig
mice
vaccin
cstppha
also
higher
control
group
intranas
administ
cstpphasplit
influenza
vaccin
could
induc
also
specif
cellmedi
immun
respons
signific
number
cell
found
spleen
cstppha
vaccin
mice
nanoparticl
prepar
use
formul
c
ratio
cstpp
absent
control
mice
includ
hasplit
viru
alon
cs
tpp
pb
stimul
group
fig
challeng
intranas
ld
mous
adapt
viru
mice
receiv
cstppha
hasplit
vaccin
alon
cstpp
pb
surviv
respect
fig
challeng
dose
increas
ld
mice
vaccin
cstppha
surviv
end
experi
day
mice
group
die
within
day
postinfect
fig
figur
show
bodi
weight
mous
group
receiv
ld
viru
challeng
mice
group
receiv
cstpphasplit
vaccin
hasplit
vaccin
group
lose
bodi
weight
first
day
challeng
respect
bodi
weight
regain
thereaft
mice
cstpp
pb
group
steadi
bodi
weight
loss
death
within
day
postinfect
morbid
mice
receiv
ld
challeng
shown
fig
cstppha
vaccin
mice
weight
loss
first
day
regain
mice
group
continu
loss
weight
becam
moribund
die
vaccin
effect
measur
prevent
influenza
first
prerequisit
step
influenza
viru
infect
occur
respiratori
epithelium
thu
immunolog
factor
oper
infect
prime
site
highli
import
prevent
viru
replic
epitheli
cell
system
spread
intramuscular
vaccin
rare
induc
local
immun
respons
also
antibodi
induc
system
parenter
vaccin
usual
reach
mucos
surfac
except
passiv
transud
would
occur
circul
igg
level
high
sustain
situat
pathotop
potenti
vaccin
administr
intranas
rout
hand
stimul
system
mucos
immun
respons
particularli
specif
secretori
iga
mucophil
proteas
resist
therefor
function
well
firstlin
defens
mucosa
howev
immunogen
acquir
mucos
vaccin
per
se
may
inadequ
thu
effect
adjuv
andor
vaccin
deliveri
vehicl
requir
improv
magnitud
immun
respons
among
variou
develop
adjuvantdeliveri
system
cs
favor
intranas
vaccin
due
mucoadhes
properti
abil
overcom
formid
nasal
epitheli
barrier
sever
studi
demonstr
success
use
cs
nanoparticl
deliveri
system
intranas
protein
dna
vaccin
studi
cs
nanoparticl
use
encapsul
hasplit
influenza
viru
vaccin
ionic
crosslink
techniqu
shear
forc
organ
solvent
heatfre
procedur
thu
suitabl
vulner
molecul
vaccin
antigen
studi
mani
factor
consid
formul
suitabl
cs
nanoparticl
vaccin
includ
concentr
cs
tpp
cstpp
mass
ratio
reagent
mix
time
therefor
preliminari
experi
perform
screen
select
best
cs
tpp
combin
format
cstpp
colloid
ionic
crosslink
cs
cation
amin
group
polyanion
tpp
phosphat
group
use
prepar
cstpp
nanoparticl
data
literatur
demonstr
spontan
particl
format
ionic
crosslinkag
occur
suitabl
concentr
cs
tpp
studi
nanoparticul
system
cstpp
good
physicochem
properti
ie
nanomet
rang
size
posit
charg
rel
high
encapsul
effici
achiev
cs
tpp
ratio
use
h
mix
time
howev
physicochem
properti
cs
nanoparticl
product
form
ioniccrosslink
affect
chemic
properti
cs
molecular
weight
degre
deacetyl
chemic
modif
condit
prepar
ph
volum
mix
time
therefor
characterist
cs
tpp
nanoparticl
produc
one
studi
may
similar
anoth
incorpor
hasplit
influenza
viru
cs
tpp
nanoparticl
done
ph
acid
ph
amin
group
cs
posit
charg
addit
hasplit
viru
product
pi
thu
ph
neg
charg
therefor
antigen
could
entrap
cstpp
nanoparticl
rel
high
percentag
encapsul
effici
accord
tem
imag
hasplit
viru
compon
might
condens
cs
polym
chain
along
tpp
form
encapsul
nanoparticl
cstppha
might
link
togeth
two
differ
bond
one
possibl
associ
mechan
vaccin
compon
nanoparticl
besid
entrap
hasplit
influenza
viru
product
cstpp
nanoparticl
electrostat
interact
cathod
cs
anod
vaccin
compon
bioadhes
cation
polymer
cs
use
prolong
resid
time
nasal
passag
promot
absorpt
cs
vaccin
via
nasal
mucosa
establish
cstppha
nanoparticl
studi
possess
posit
surfac
charg
mv
indic
suitabl
properti
intranas
vaccin
deliveri
posit
charg
cstppha
bind
neg
charg
mucu
glycoprotein
also
dendrit
dendrit
cell
dc
protrud
paracellular
junction
epitheli
cell
intim
contact
vaccin
formul
mucusmucosa
increas
retent
time
cstppha
vaccin
increas
absorpt
opportun
nasal
mucosa
bind
nanoparticl
dendrit
cell
allow
antigen
deliveri
cytoplasm
antigen
process
via
cytosol
pathway
mhc
class
follow
immun
respons
stimul
phagocytos
compon
process
peptid
present
via
mhc
class
ii
pathway
humor
immun
respons
induc
moreov
crossantigen
present
could
expect
also
size
known
influenc
mucos
uptak
particul
deliveri
system
howev
optim
size
nasal
vaccin
deliveri
vehicl
still
controversi
mani
studi
reveal
stronger
robust
immun
respons
induc
submicron
size
cs
nanoparticl
particl
size
rang
readili
phagocytos
antigenpres
cell
data
mucu
adsorpt
studi
reveal
mucoadhes
particl
fine
nanoparticl
nm
increas
penetr
mucu
layer
hand
larger
particl
adsorb
surfac
mucosa
langmuirtyp
adsorpt
cs
ionic
crosslinkingha
nanoparticl
studi
appropri
size
nm
measur
use
zetas
particl
appli
intranas
engulf
microfold
cell
overli
nasal
associ
lymphoid
tissu
intact
antigen
deliv
appropri
follicular
dendrit
cell
local
immun
respons
stimul
antigen
may
carri
dc
local
drain
lymph
node
distant
lymphoid
tissu
immun
respons
incit
therein
abil
cstppha
induc
system
mucos
immun
respons
demonstr
studi
high
level
haspecif
serum
igg
antibodi
cell
spleen
specif
iga
antibodi
balf
nw
respect
immunogen
cstppha
split
vaccin
hasplit
vaccin
alon
demonstr
also
former
vaccin
formul
could
provid
higher
protect
efficaci
latter
low
high
lethal
challeng
ld
respect
highli
virul
influenza
viru
mice
vaccin
intranas
cs
nanoparticleentrap
hasplit
vaccin
surviv
lethal
infect
partial
protect
observ
mice
receiv
hasplit
vaccin
alon
low
high
dose
respect
overal
result
indic
cs
nanoparticl
prepar
produc
studi
suitabl
deliveri
vehicleadjuv
enhanc
influenza
vaccin
immunogen
also
increas
encapsul
vaccin
protect
efficaci
unfortun
experi
compar
adjuvant
cs
nanoparticl
approv
human
vaccin
adjuv
alum
waterinoiloilinwaterwaterinoilin
water
emuls
done
hasplit
influenza
vaccin
suitabl
condit
product
cstpp
nanoparticl
mean
ionic
crosslink
studi
nanoparticl
use
success
deliveri
vehicl
hasplit
influenza
viru
vaccin
intranas
immun
mice
receiv
cstpp
nanoparticleencapsul
hasplit
influenza
vaccin
intranas
develop
higher
system
mucos
antibodi
respons
vaccin
made
hasplit
influenza
viru
alon
nanoparticleencapsul
vaccin
could
induc
also
cellmedi
immun
respons
shown
high
number
cell
spleen
ha
vaccin
alon
could
besid
cs
nanoparticleencapsul
hasplit
vaccin
reduc
markedli
influenza
morbid
confer
protect
rate
vaccin
mice
lethal
influenza
viru
challeng
taken
togeth
cs
nanoparticl
invent
studi
effect
safe
deliveri
vehicleadjuv
monoval
hasplit
influenza
vaccin
test
investig
multival
hasplit
vaccin
univers
influenza
vaccin
made
influenza
viru
conserv
protein
matrix
ion
channel
protein
nucleoprotein
np
multifunct
nonstructur
